{"entity":{"id":"bpx-601","kind":"drug","name":"BPX-601","aka":[],"tldr":"BPX-601 is an experimental autologous CAR-T cell therapy from Bellicum Pharmaceuticals, in phase 1 trials for metastatic castration-resistant prostate cancer.","summary":"BPX-601 is an autologous CAR-T cell therapy (GoCAR platform) from Bellicum Pharmaceuticals, with Regeneron Pharmaceuticals as acquirer. An autologous GoCAR-T product containing Bellicum's inducible MyD88/CD40 (iMC) activation switch, designed to treat solid tumours expressing prostate stem cell antigen (PSCA). Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Bellicum discontinued its trial in March 2023, but ClinicalTrials.gov now lists Regeneron Pharmaceuticals as sponsor of a new phase 1 (NCT07543055, recruiting, start 8 Sept 2026) and of the earlier NCT02744287 (terminated). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Bellicum Pharmaceuticals: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm"},{"label":"Bellicum Pharmaceuticals: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07543055"},{"label":"ClinicalTrials.gov: trials of BPX-601","url":"https://clinicaltrials.gov/search?intr=BPX-601"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":["psca"],"drugs":[],"companies":["bellicum","regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07543055","nct02744287"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BPX-601","modality":"Autologous CAR-T cell therapy (GoCAR platform)","mechanism":"An autologous GoCAR-T product containing Bellicum's inducible MyD88/CD40 (iMC) activation switch, designed to treat solid tumours expressing prostate stem cell antigen (PSCA).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bpx-601/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"target":[{"id":"psca","kind":"target","name":"PSCA","route":"/targets/psca/"}],"company":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}],"trial":[{"id":"nct07543055","kind":"trial","name":"A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread","route":"/trials/nct07543055/"},{"id":"nct02744287","kind":"trial","name":"Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors","route":"/trials/nct02744287/"}]}}